Kroesen BJ - Search Results

1

Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1.

Schröder CP, Kroesen BJ, de Leij LF, de Vries EG. Schröder CP, et al. Among authors: kroesen bj. Clin Cancer Res. 2000 Jun;6(6):2521-7. Clin Cancer Res. 2000. PMID: 10873108

2

Increased production of antigen-specific B lymphocytes during in vitro immunization using carrier-specific T helper hybridomas.

Schilizzi BM, Kroesen BJ, The TH, de Leij L. Schilizzi BM, et al. Among authors: kroesen bj. J Immunol Methods. 1992 Aug 30;153(1-2):49-56. doi: 10.1016/0022-1759(92)90304-c. J Immunol Methods. 1992. PMID: 1387673

3

Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence.

Kroesen BJ, Mesander G, ter Haar JG, The TH, de Leij L. Kroesen BJ, et al. J Immunol Methods. 1992 Nov 25;156(1):47-54. doi: 10.1016/0022-1759(92)90009-i. J Immunol Methods. 1992. PMID: 1431162

4

Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.

Kroesen BJ, Bakker A, van Lier RA, The HT, de Leij L. Kroesen BJ, et al. Cancer Res. 1995 Oct 1;55(19):4409-15. Cancer Res. 1995. PMID: 7545540

5

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Janssen RA, Kroesen BJ, Buter J, Mesander G, Sleijfer DT, The TH, Mulder NH, de Leij L. Janssen RA, et al. Among authors: kroesen bj. Br J Cancer. 1995 Sep;72(3):795-9. doi: 10.1038/bjc.1995.414. Br J Cancer. 1995. PMID: 7669598 Free PMC article. Clinical Trial.

6

Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model.

Kroesen BJ, Helfrich W, Bakker A, Wubbena AS, Bakker H, Kal HB, The TH, de Leij L. Kroesen BJ, et al. Int J Cancer. 1995 Jun 9;61(6):812-8. doi: 10.1002/ijc.2910610612. Int J Cancer. 1995. PMID: 7790116

7

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH, Berendsen HH, Limburg PC, The TH, et al. Kroesen BJ, et al. Cancer Immunol Immunother. 1993 Nov;37(6):400-7. doi: 10.1007/BF01526797. Cancer Immunol Immunother. 1993. PMID: 7902211 Free PMC article.

8

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf WT, The TH, de Leij L, Mulder NH. Kroesen BJ, et al. Br J Cancer. 1994 Oct;70(4):652-61. doi: 10.1038/bjc.1994.366. Br J Cancer. 1994. PMID: 7917912 Free PMC article. Clinical Trial.

9

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.

Kroesen BJ, Janssen RA, Buter J, Nieken J, Sleijfer DT, Mulder NH, De Leij L. Kroesen BJ, et al. J Hematother. 1995 Oct;4(5):409-14. doi: 10.1089/scd.1.1995.4.409. J Hematother. 1995. PMID: 8581377 Clinical Trial.

10

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity.

Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, de Leij L. Kroesen BJ, et al. Br J Cancer. 1996 Mar;73(6):721-7. doi: 10.1038/bjc.1996.127. Br J Cancer. 1996. PMID: 8611371 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters